EP4153613A4 - Il1-r1 derived inhibitor of il-1b and use thereof - Google Patents

Il1-r1 derived inhibitor of il-1b and use thereof

Info

Publication number
EP4153613A4
EP4153613A4 EP20936359.7A EP20936359A EP4153613A4 EP 4153613 A4 EP4153613 A4 EP 4153613A4 EP 20936359 A EP20936359 A EP 20936359A EP 4153613 A4 EP4153613 A4 EP 4153613A4
Authority
EP
European Patent Office
Prior art keywords
derived inhibitor
inhibitor
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20936359.7A
Other languages
German (de)
French (fr)
Other versions
EP4153613A1 (en
Inventor
Yan Lavrovsky
Alexey Repik
Mikhail Samsonov
Sergei Barbashov
Vasily Ignatiev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R-PHARM OVERSEAS Inc
R Pharm Overseas Inc
Original Assignee
R-PHARM OVERSEAS Inc
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R-PHARM OVERSEAS Inc, R Pharm Overseas Inc filed Critical R-PHARM OVERSEAS Inc
Publication of EP4153613A1 publication Critical patent/EP4153613A1/en
Publication of EP4153613A4 publication Critical patent/EP4153613A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP20936359.7A 2020-05-22 2020-05-22 Il1-r1 derived inhibitor of il-1b and use thereof Pending EP4153613A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/034114 WO2021236091A1 (en) 2020-05-22 2020-05-22 Il1-r1 derived inhibitor of il-1b and use thereof

Publications (2)

Publication Number Publication Date
EP4153613A1 EP4153613A1 (en) 2023-03-29
EP4153613A4 true EP4153613A4 (en) 2024-01-24

Family

ID=78708753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20936359.7A Pending EP4153613A4 (en) 2020-05-22 2020-05-22 Il1-r1 derived inhibitor of il-1b and use thereof

Country Status (6)

Country Link
EP (1) EP4153613A4 (en)
JP (1) JP2023527171A (en)
CN (1) CN115768787A (en)
BR (1) BR112022022089A2 (en)
MX (1) MX2022014410A (en)
WO (1) WO2021236091A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1016673B1 (en) * 1992-10-02 2006-02-01 Genetics Institute, LLC Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
AU2013378122B2 (en) * 2013-02-15 2019-05-02 R-Pharm International, Limited Liability Company IL-1beta inhibitor composition and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ECONOMIDES A N ET AL: "Cytokine traps: multi-component, high-affinity blockers of cytokine action", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 9, no. 1, 1 January 2003 (2003-01-01), pages 47 - 52, XP002256034, ISSN: 1078-8956, DOI: 10.1038/NM811 *
See also references of WO2021236091A1 *

Also Published As

Publication number Publication date
MX2022014410A (en) 2022-12-06
CN115768787A (en) 2023-03-07
BR112022022089A2 (en) 2022-12-13
JP2023527171A (en) 2023-06-27
WO2021236091A1 (en) 2021-11-25
EP4153613A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
GB2595975B (en) Inhibitors of cysteine proteases and methods of use thereof
IL287787A (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL287795A (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP4143196A4 (en) PI3K-a INHIBITORS AND METHODS OF USE THEREOF
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
IL287973A (en) Acss2 inhibitors and methods of use thereof
IL284661A (en) Pcsk9 inhibitors and methods of use thereof
EP4125831A4 (en) Kcnt1 inhibitors and methods of use
IL304728A (en) Cdk2 inhibitors and methods of using the same
IL299245A (en) Lair-1-binding agents and methods of use thereof
GB202319843D0 (en) CAS13-based compositions and methods of use thereof
IL264854A (en) Spt5 inhibitors and methods of use thereof
EP4142740A4 (en) Compositions and methods of use thereof
EP4153613A4 (en) Il1-r1 derived inhibitor of il-1b and use thereof
IL311588A (en) Lpxc inhibitors and uses thereof
IL299700A (en) Kcnt1 inhibitors and methods of use
EP4110317A4 (en) Kcnt1 inhibitors and methods of use
GB2613900B (en) Novel compounds and methods of use thereof
EP4124344A4 (en) Novel use of hic-5 inhibitor
GB202208124D0 (en) Inhibitors of expression and/or function
GB202208122D0 (en) Inhibitors of expression and/or function
EP4186908A4 (en) Jak inhibitor compound and use thereof
GB202315697D0 (en) Compounds and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALI20231221BHEP

Ipc: A61P 19/02 20060101ALI20231221BHEP

Ipc: A61P 3/10 20060101ALI20231221BHEP

Ipc: A61P 3/00 20060101ALI20231221BHEP

Ipc: A61P 43/00 20060101ALI20231221BHEP

Ipc: C07K 19/00 20060101ALI20231221BHEP

Ipc: A61K 38/20 20060101ALI20231221BHEP

Ipc: C07K 14/545 20060101AFI20231221BHEP